Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fungal cells causing onychomycosis primarily include dermatophytes such as Trichophyton rubrum and Trichophyton mentagrophytes, which account for the majority of cases (StatPearls, 2023). These pathogens also encompass various yeasts, such as Candida albicans, and non-dermatophyte molds that invade the nail unit, including the nail plate and bed (NIH, 2022). The biological role of these cells in disease involves the secretion of keratinases that degrade nail keratin, facilitating fungal colonization and persistence (PubMed, 2021). Pharmacological intervention targets specific molecular pathways within these cells, most notably the ergosterol biosynthetic pathway and protein synthesis machinery (Journal of Fungi, 2021). Drugs like terbinafine and efinaconazole work by inhibiting enzymes like squalene epoxidase and 14-alpha demethylase, respectively, leading to membrane disruption and cell death (FDA, 2020). Because the nail plate acts as a physical barrier, these fungal cells are often difficult to eradicate, requiring long-term systemic or topical therapy (Mayo Clinic, 2023).
Antifungal drugs target these cells by inhibiting ergosterol biosynthesis (via squalene epoxidase or 14-alpha demethylase inhibition), disrupting protein synthesis (via leucyl-tRNA synthetase inhibition), or interfering with fungal cell membrane integrity and intracellular transport.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Onychomycosis-causing fungal pathogens.